Posts Tagged: pharmaceuticals


A Misguided Op-Ed, a Key Report, and Why Holding the U.S. Lead in the Life Sciences is More Important Than Ever

Our current experiences with COVID-19 in the United States, together with headlines warning of major efforts by the Chinese and Russian governments to hack corporate, academic and …
By Joseph Allen
4 months ago 6

IP Valuation for the Preservation of Public Health: Managing IP in the Age of COVID-19

Certainly, patents that read on a potential cure for COVID-19 deserve special treatment. After all, the cure for COVID-19 is not only crucial to save lives all …
By Roya Ghafele
5 months ago 0

WHO’s C-TAP Initiative Pushes for Non-Exclusive Global Licensing Amid Pharma Industry Concerns

On Friday, May 29, the World Health Organization (WHO) officially launched the COVID-19 Technology Access Pool (C-TAP), an initiative which is intended to improve access to treatments, vaccines …
By Steve Brachmann
6 months ago 2

Efforts to Villainize Biotech, Pharma over COVID-19 are Political Theater and Opportunism

If the objective is to beat this virus as fast as possible it simply isn’t helpful to talk about the compulsory licensing of drugs that don’…
By Gene Quinn
8 months ago 11

Innovators Rush to Solve Coronavirus Pandemic While Countries Contemplate Compulsory Licensing

Since China announced the first fatality caused by a virus about which little was known at the time, coronavirus and the disease it causes, COVID-19, has grown …
By Steve Brachmann
8 months ago 2

We Won’t Stop Coronavirus Without IP

The recent White House meeting with leaders from American pharmaceutical companies sought their help in solving the coronavirus that originated in Wuhan, China and is currently gripping …
By James Edwards
9 months ago 16

Responding to Criticism of ‘State Pharmaceutical Importation Programs Threaten Patients and Innovation’

A recent article by Dr. Kristina M. L. Acri née Lybecker highlighted her research about the fiscal workability of state pharmaceutical importation programs from two important …
By Shabbir Imber-Safdar
10 months ago 22

State Pharmaceutical Importation Programs Threaten Patients and Innovation

In mid-December, President Trump presented a plan to lower prescription drug prices by allowing states, drug wholesalers and pharmacies to import some cheaper drugs from Canada. While …

The Fifth Circuit Must Preserve the Patent-Antitrust Balance by Upholding Actavis

The pharmaceutical industry presents some of the most important and challenging issues lying at the intersection of the patent and antitrust laws. On the one hand, patents …
By Michael Carrier
11 months ago 0

U.S. Government Patent Enforcement: A Ripple or a Coming Tempest?

In most respects, the widely reported patent complaint recently filed against Gilead is perfectly ordinary. It was filed in the U.S. District Court for the District …
By Chad Landmon & Jonathan Knowles
12 months ago 4

Curing the Drug Label as Prior Art Malady at the PTAB

Petitioners challenging patents covering pharmaceuticals and biologics often use drug product labels as prior art in the Patent Trial and Appeal Board (PTAB). To effectively use a …

Federal Circuit Decision Delays Generic Osteoarthritis Drug

On October 9, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a decision in HZNP Medicines LLC v. Actavis Laboratories UT, Inc. affirming the …
By Nancy Braman
1 year ago 2

Proper Interpretation of Section 3(d) of the Indian Patent Act Could Save Incremental Innovations of Existing Pharmaceutical Substances

The landmark judgment of the Supreme Court of India in Novartis AG & Ors. .v. Union of India & Ors. AIR 2013 SC 1311, a case that dealt with the patenting …
By Naresh Asuri
1 year ago 0

House Drug Pricing Hearing Goes Off Script

Most Congressional hearings are morality plays designed to reach a predetermined outcome. It wasn't hard to predict how the second hearing on drug pricing by the House …
By Joseph Allen
2 years ago 5

Affordable Prescriptions for Patients Act Would Allow FTC to Prosecute Pharma Patent Thickets, Product Hopping

On Thursday, May 9, the Affordable Prescriptions for Patients (APP) Act was introduced into the U.S. Senate by Senators John Cornyn (R-TX) and Richard Blumenthal (D-CT). If …
By Steve Brachmann
2 years ago 1